Heartburn medication recalls continue, generic versions of Zantac included
Just when you think it’s safe to resume using your favorite name brand or generic heartburn medication, the U. S. Food and Drug Administration announces a new round of recalls. Once again, generic versions of Zantac are being recalled due to the presence of a “probable human carcinogen”. You shouldn’t be surprised to learn that the carcinogen is none other than N-Nitrosodimethylamine (NDMA).
Denton Pharma Inc. and their generic Zantac drug “Ranitidine” is the focus of the latest recall. The tablets were packaged and sold in lots of 150mg and 300mg strengths. The recalls aren’t limited to Denton Pharma though, Appco Pharma and a company named Mylan have announced recalls due to possible carcinogens. The Appco Pharma meds have expiration dates of April and May 20201, so there’s a good chance they’re still in your medicine cabinet. As for the Mylan recall, their recall was for an antacid known as ‘nizatidine’, “which was also found to contain trace amounts of NDMA. Those capsules, in 150mg and 300mg strengths, were manufactured by Solara Active Pharma Sciences Limited.”
So far, the U.S. Food and Drug Administration has received no reports of illnesses or injuries related to these medications. Furthermore, famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (Nexium), lansoprazole (Prevacid) and omeprazole (Prilosec) are thought to be NDMA free, as they have yet to test positive for the possible human carcinogen.
For more information on this developing story, follow this link: https://nbcnews.to/2Rd6rAe